AT 2.25 MG/m2 IV WEEKLY
COMPLETE REMISSION RATE 4.6%
WITH OF COURSE NEUROPATHY IN ALMOST 40% OF PATIENTS
BUT EFFECTIVE EVEN WITHOUT ASPARAGINASE
Liposomal encapsulation prolongs its presence in the blood and ability to penetrate the marrow, lymph nodes and spleen).
------------------------------------------------------------------
Jakafi, for your Myelofibrosis patient with positive JAK2V617F positive and negative patient
with a 35% reduction in splenomegaly at 24 weeks occurring in 41% of patients.
will check out the JAK signaling!
A blog about research, awareness, prevention, treatment and survivorship of Breast Cancer and all cancers, including targeted scientific research and a grassroots approach to increase screening for cancer, especially in the low income and under-insured population of El Paso, Texas, with a view to expand this new health care model to many other 'minority' populations across the United States and beyond
Showing posts with label JAK2V617F. Show all posts
Showing posts with label JAK2V617F. Show all posts
Friday, January 18, 2013
NEW LIPOSOMAL VINCRISTINE WITH EFFICACY IN RELAPSE/REFRACTORY PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Subscribe to:
Posts (Atom)